| abstract |
A combined preparation, comprising: (a) LAG-3 protein, or a derivative thereof which can bind to MHC class II molecules and which comprises an amino acid sequence having at least 70% amino acid identity with the D1 domain, and optionally D2 domain, of the LAG-3 protein; and (b) an antineoplastic agent, where the antineoplastic agent is a platinum-based antineoplastic agent or a topoisomerase I inhibitor. |